| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Aortic aneurysm (AA) is a serious and life-threatening disease. Although significant advances have been made in open surgery and endovascular repair, no medical therapies are available to prevent AA growth. Appearance of many M1MF is observed along with secretion of proinflammatory cytokines and chemokines in AA progression. Equal proportions of M1/M2 leads to aneurysm stability, whereas increased population of M1MF predisposes the aneurysm to rupture. We hypothesized that inducing the high dominant localization of M2MF at the lesion site of AA and regulating the M1/M2 ratio might be a therapeutic strategy of AA treatment.
M1MF had significantly decreased gene expressions by M2MF co-culture. M2MF exhibited significant decrease MMP-9 compared with AA tissue mono-culture. Administration of M2MF inhibited AA expansion through the improvement of inflammatory reaction with the dominance of M2MF. This study provides that M2MF administration might be useful for the treatment of AA.
|
